Platelet-derived Growth Factor β-Receptor, Transforming Growth Factor β Type I Receptor, and CD44 Protein Modulate Each Other’s Signaling and Stability*

Received for publication, January 13, 2014, and in revised form, May 20, 2014. Published, JBC Papers in Press, May 23, 2014, DOI 10.1074/jbc.M114.547273

Helena Porsch, Merima Mehić, Berit Olofsson, Paraskevi Heldin, and Carl-Henrik Heldin

From the Ludwig Institute for Cancer Research, Science for Life Laboratory, Uppsala University, Biomedical Center, Box 595, SE-75124 Uppsala, Sweden

Background: The hyaluronan receptor CD44 interacts with the PDGF β-receptor and the TGFβ type I receptor.

Results: CD44, PDGF β-receptor and TGFβ type I receptor affect each other’s signaling, stability and function.

Conclusion: Cross-talk between PDGF β-receptor and TGFβ type I receptor occurs in human dermal fibroblasts.

Significance: This study reveals novel modulatory mechanisms of PDGF and TGFβ signaling.

Platelet-derived growth factor (PDGF) isoforms potently stimulate growth, migration, and survival of cells via binding to α- and β-tyrosine kinase receptors (PDGFRα and PDGFRβ, respectively) (1). Ligand binding induces dimerization of the receptors followed by activation by autophosphorylation. The phosphorylated PDGF receptors provide docking sites for a wide variety of signaling molecules and adaptor proteins, including the following: Grb2, which forms a complex with the nucleotide exchange factor Sos1, leading to activation of Ras and the ERK MAPK pathway; phospholipase Cγ, which mediates activation of protein kinase C; phosphoinositide-3-kinase (PI3K), which activates the Akt kinase, the tyrosine phosphatase SHP2, the tyrosine kinase Src, and members of the STAT family (2). After ligand binding, the receptor complex is internalized and subsequently degraded, resulting in termination of the signaling (3).

TGFβ transmits its signals via formation of a heterotrimeric complex of type I (TβRI) and type II (TβRII) receptor serine/threonine kinases. Upon binding of TGFβ to TβRII, TβRI is recruited to the complex, where it is phosphorylated and activated by TβRII. Activated TβRI phosphorylates receptor-activated Smads (R-Smads), Smad2 and Smad3, which then bind to the common mediator, Smad4, and after translocation into the nucleus they regulate the expression of certain genes (4). TGFβ also induces activation of non-Smad pathways, including the ERK, JNK, and p38 MAPK pathways, as well as PI3K/Akt (5). Moreover, TβRI undergoes ligand-dependent intramembrane proteolysis, which releases its intracellular domain that, after translocation to the nucleus, drives an invasiveness program (6).

TβRI undergoes constitutive internalization even in the absence of TGFβ, but its down-regulation may be enhanced by ligand binding (7), and enhanced signaling by clathrin-mediated endocytosis has been reported (8, 9). TGFβ inhibits cell proliferation, modulates differentiation, and induces apoptosis of most epithelial, endothelial, and hematopoietic cells (10). Notably, TGFβ has a dual role during cancer development; at early stages of carcinogenesis, it acts as a tumor suppressor, although at later stages it promotes invasiveness and metastasis, e.g. through induction of epithelial-mesenchymal transition (EMT) (10–12).

Ligand access to TGFβ receptors is negatively regulated by traps that sequester the ligand and block its binding to the receptors (4). These ligand traps include the latency-associated polypeptide of the TGFβ precursor, and the small proteoglycan...
decorin and \(\alpha_2\)-macroglobulin. The latency-associated poly-peptide is bound to the latent TGF\(\beta\)-binding proteins (LTBP1, 3, 4), and dissociation from this complex is needed for activation of latent TGF\(\beta\). Integrins, proteases, thrombospondin 1, heat, and high and low pH values have been demonstrated to activate latent TGF\(\beta\) (13).

CD44 is a principal receptor for the large glycosaminoglycan hyaluronan; it lacks kinase activity but influences cell behavior by several mechanisms (14, 15). First, the intracellular domain of CD44 interacts with key regulators of the actin cytoskeleton, including ankyrin, members of the ezrin, radixin, moesin (ERM) family of proteins, IQGAP (16, 17), and proteins affecting cell survival, such as the tumor suppressor protein Merlin (18). Second, CD44 can be cleaved in the transmembrane region and the intracellular part translocates to the nucleus where it binds to the cyclin D1 promoter, thereby enhancing region and the intracellular part translocates to the nucleus,

ing cell survival, such as the tumor suppressor protein Merlin (18). Third, CD44 functions as a co-receptor where it binds to the cyclin D1 promoter, thereby enhancing

ing TGF\(\beta\) (31). PDGFR expression is induced in breast epithelial cells during TGF\(\beta\)-induced EMT (32, 33), and PDGF signaling mainly regulates with metastasis and bad prognosis in breast carcinoma (30), and expression of PDGF ligand correlated with metastasis and bad prognosis in breast carcinoma (31). PDGFR expression is induced in breast epithelial cells during TGF\(\beta\)-induced EMT (32, 33), and PDGF signaling maintains EMT and promotes breast cancer metastasis (34). TGF\(\beta\)-mediated tumor progression in hepatocytes is also dependent on PDGF signaling (35). In a bioinformatics screen, expression of PDGFR was strongly associated with genes involved in EMT and metastasis in all the cohorts analyzed (33). Because CD44 interacts with both PDGFR and T\(\beta\)RI, we explored the possibility that CD44 simultaneously interacts with the receptors for PDGF and TGF\(\beta\), and facilitates crosstalk between them.

**MATERIALS AND METHODS**

**Constructs and Vectors**—The pcDNA3-PDGFR\(\beta\)-HA plasmid (37) and pcDNA3.1 Hygro-CD44H-6myc (38) were generous gifts from Drs. A. Östman (Karolinska Institutet, Stockholm, Sweden) and S. Lammich (Ludwig Maximilian University, Munich, Germany), respectively. The FLAG-tagged T\(\beta\)RI-expressing vector has been described (39, 40). An HA-tagged truncated PDGFR\(\beta\) mutant expressing only the extracellular and transmembrane parts of the receptor (40) was cloned from the pcDNA3-PDGFR\(\beta\) vector by inserting a novel XhoI site 36 nucleotides into the intracellular domain using site-directed mutagenesis (Stratagene), cleavage of the truncated protein using EcoRI and XhoI, and insertion into an HA-tagged pcDNA3 vector (HA tag C-terminally located between XhoI and XbaI). As negative controls, empty pcDNA3 vectors (either untagged or tagged with HA, FLAG, or 6myc) were used. Plasmids were amplified using Qiagen® plasmid maxi kit.

**Cell Culture**—Cos1 (monkey kidney fibroblast-like cells; ATCC CRL-1650), primary human dermal fibroblasts from normal breast tissue (biopsies were taken after approval from patients undergoing breast reduction surgery at the Department of Plastic Surgery of University Hospital, Uppsala, Sweden (17)), and BJ-hTERT (telomerase immortalized human foreskin fibroblasts) cells (41) were routinely cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen), supplemented with 10% fetal bovine serum (FBS; HyClone) at 37°C in 5% CO2. Prior to stimulation, cells were starved for 24 h in DMEM supplemented with 0.1% FBS (Cos1 cells and BJ-hTERT) or 2% FBS (dermal fibroblasts) and then treated for 7 min to 24 h with TGF\(\beta\)1 (PeproTech EC Ltd.; 1–5 ng/ml), PDGF-BB (Creative Biomolecules; 2–20 ng/ml), or hyaluronan (high molecular weight, Q-med; 200 µg/ml). Pretreatment with PDGFR\(\beta\) inhibitor AG1296 (Calbiochem; 10 µM) or imatinib (Novartis, 5 µM), Src kinase inhibitor SU6656 (Calbiochem 1.5 µM), cycloheximide (Sigma, 20 µM), or TGF\(\beta\)-neutralizing antibody (R&D Systems; 20 µg/ml) was for 1 h, and pretreatment with T\(\beta\)RI inhibitor GW6604 (American Custom Chemicals Corp.; 16 µM) was for 2 h. Inhibitors remained present during stimulation.

**Transient Transfections**—Cos1 cells (1 × 10⁶ cells/6-cm culture dish) were transiently transfected with 0.1–2 µg each of vectors encoding PDGFR\(\beta\)-HA, T\(\beta\)RI-FLAG, T\(\beta\)RII-FLAG, and/or PDGFR\(\beta\)-ECTM-HA for 48 h using Lipofectamine 2000 (Invitrogen), according to the instructions of the manufacturer. siRNA against CD44 or PDGFR\(\beta\) (SmartPool, Dharmaco) was transiently transfected using SilentFECT (Bio-Rad) according to the instructions of the manufacturer. Cells were treated for 72 h with 15 nM PDGFR\(\beta\) siRNA, 10 nM CD44 siRNA (Cos1 cells), or 25 nM CD44 siRNA (dermal fibroblasts and BJ-hTERT), starved for 24 h, and then stimulated with PDGF-BB or TGF\(\beta\).

**Protein Extraction and Immunoprecipitation**—Cells were washed in ice-cold phosphate-buffered saline (PBS) and then lysed in cell lysis buffer (0.5% Triton X-100, 0.5% sodium deoxycholate, 20 mM Tris, pH 7.4, 150 mM NaCl, 10 mM EDTA), with protease and phosphatase inhibitors (0.5 mg/ml Pefabloc, 10 µM leupeptin, 1 µM pepstatin, 100 KIU/ml aprotinin, and 1 mM sodium orthovanadate). Following centrifugation (10,000 g, 10 min, 4°C), the supernatants were either boiled in reducing SDS-sample buffer and analyzed by SDS-PAGE or subjected to immunoprecipitation. For immunoprecipitation, lysates were precleared with 10 µl of protein G-Sepharose beads (GE Healthcare; 50% slurry in PBS) end-over-end at 4°C for 1 h. Following centrifugation (300 × g, 5 min, 4°C), supernatants were incubated with 3 µg of primary antibody (polyclonal rabbit T\(\beta\)RI antibody sc-398, polyclonal rabbit HA antibody sc-805, monoclonal mouse c-Myc antibody sc-40, Santa Cruz Biotechnology) or monoclonal mouse FLAG-M2 antibody F-3165 (Sigma) end-over-end at 4°C overnight. The immune complexes were captured by 25 µl of protein G-Sepharose beads with end-over-end mixing for 1 h at 4°C. Beads were washed three times in cell lysis buffer, then one time in 0.5 M...
NaCl, and once more in cell lysis buffer. To elute the captured proteins, 20 μl of reducing SDS-sample buffer was added, and the samples were boiled at 95 °C for 5 min. Beads were removed by centrifugation at 300 × g for 5 min, and the supernatant was analyzed by SDS-PAGE and immunoblotting.

**SDS-PAGE and Immunoblotting**—Cell lysates were analyzed by SDS-PAGE, and proteins were transferred to Hybond C Extra nitrocellulose membranes (Amersham Biosciences). Membranes were blocked by incubation in 5% milk or 5% bovine serum albumin (BSA) in Tris-buffered saline (TBS), 0.1% Tween 20 and incubated with primary antibodies (diluted in 1% BSA in TBS, 0.1% Tween 20, 0.02% NaN₃) as follows: polyclonal rabbit TβRI antiserum or monoclonal mouse Y99 phosphotyrosine antibody (Santa Cruz Biotechnology); monoclonal mouse CD44 antibody (Hermes3; a kind gift from Dr. S. Jalkanen, University of Helsinki, Finland (42)); rabbit polyclonal PDGFRα (CTβ; homemade (43)); rabbit polyclonal phospho-Smad2 (homemade (44)); rabbit polyclonal Smad2 (Epitomics) antisera; mouse monoclonal PA11 (BD Biosciences), or GAPDH (Ambion) antibodies. Proteins were visualized by chemiluminescence and exposed to x-ray film. Between each step, the membranes were washed three times for 5 min in TBS, 0.1% Tween 20. To quantify band intensities, scanner and densitometric software (ImageJ) was used.

**Proximity Ligation Assay (PLA)**—Proximity ligation assay was performed with the Duolink system (Olink Bioscience) according to the instructions from the manufacturer. Briefly, BJ-hTERT fibroblasts were grown in 8-well chamber slides (BD Biosciences), starved, stimulated with 10 ng/ml PDGF-BB for 10 min, 1 ng/ml TGFβ for 1 h, or 200 μg/ml hyaluronan for 2 h, and washed in PBS. After fixation in 3% paraformaldehyde and blocking in Duolink solution, primary antibodies against PDGFRβ (B2; a kind gift from Dr. K. Rubin, Uppsala University, Sweden), TβRI (H100; Santa Cruz Biotechnology), or CD44 (Hermes3) were applied. Addition of secondary antibodies conjugated with PLA probes and ligation was followed by rolling circle amplification. Cells were counterstained with fluorescein isothiocyanate (FITC)-phalloidin (Sigma) and 4',6-diamidino-2-phenylindole (DAPI) and mounted with Prolong Gold Anti-Fade (Invitrogen). Images of the cells were taken with a Zeiss Axioplan2 microscope, and signals were quantified with Duolink Image Tool software (Olink Biosciences).

**Biotinylation Assay**—Human dermal primary fibroblasts were transfected with siRNA against PDGFRα, starved, and stimulated with 10 ng/ml PDGF-BB or 1 ng/ml TGFβ for up to 1 h. Cells were rinsed on ice with PBS, pH 7.4, and twice with PBS, pH 8.0. Then cell surface proteins were biotinylated by incubation with 0.3 mg/ml EZ-link Sulfo-NHS-SS-biotin (Thermo Scientific) in PBS, pH 8.0, for 20 min on ice at 4 °C. Unbound biotin was quenched by 50 mM Tris, pH 8.0, for 10 min on ice, and cells were lysed. Biotinylated proteins were captured with streptavidin-conjugated magnetic Sepharose beads (GE Healthcare) for 30 min at 4 °C, and biotinylated PDGFRα and TβRI were visualized by SDS-PAGE and immunoblotting.

**Scratch Wound Migration Assay**—Confluent human dermal primary fibroblasts were starved for 24 h and wounded by scratching with a pipette tip. Following gentle washing, cells were pretreated with GW6604 (16 μM) for 2 h before cells were incubated with 2 ng/ml PDGF-BB for 24 h. Phase contrast images of wounded areas were taken at time 0 and 24 h after stimulation. Wounded areas covered by cells were quantified using T-scratch software (CSElab), and migration of cells was determined as the part of the wounded area that had been covered by cells.

**Statistics**—Stimulated and unstimulated samples were assumed to be paired in individual experiments; ratio paired t test was used for normally distributed data, and Wilcoxon matched pair signed rank test was used for skewed data to calculate p values in GraphPad Prism 6. p values below 0.05 were considered to be significant.

**RESULTS**

**PDGFRβ Forms a Noninducible Complex with TβRI and TβRII**—We explored the possibility that the receptors for PDGF-BB and TGFβ interact with each other in Cos1 cells overexpressing HA-tagged PDGFRβ and FLAG-tagged TβRI. Immunoprecipitation with an antibody against HA followed by immunoblotting with FLAG antibody revealed a band of the expected size of TβRI. Conversely, immunoprecipitation with a FLAG antibody followed by immunoblotting with an HA antibody revealed a band of the expected size of PDGFRβ. These observations suggest that the two receptors occur in the same complex (Fig. 1A, left panel). To investigate whether the interaction was mediated through the extracellular or intracellular domain of PDGFRβ, co-immunoprecipitation was performed with an HA-tagged PDGFRβ mutant expressing only the extracellular and transmembrane region (PDGFRβ-ECTM-HA). Immunoblotting analysis revealed that TβRI interacts also with this truncated form of PDGFRβ, suggesting that TβRI binds to the extracellular or transmembrane parts of PDGFRβ (Fig. 1B). Using the same approach, but with cells overexpressing FLAG-TβRII together with HA-PDGFRβ, an interaction between PDGFRβ and TβRII was also observed (Fig. 1A, right panel).

To gain insights into how the activation states of the receptors affect the complex formation, we cultured Cos1 cells overexpressing HA-PDGFRβ and FLAG-TβRI in the absence or presence of PDGF-BB or TGFβ, as well as inhibitors of the kinase activities of PDGFRβ (imatinib) or TβRI (GW6604). Treatments with ligands or inhibitors of the receptor kinases had no effect on the complex between PDGFRβ and TβRI, as shown by immunoprecipitation of TβRI with FLAG antibodies, followed by immunoblotting of PDGFRβ with HA antibodies (Fig. 1C). TβRII was co-transfected with the other receptors to ensure TGFβ binding to TβRI; immunoblotting with a phospho-Smad2 antisem confirmed that Smad2 was phosphorylated in response to TGFβ stimulation and was inhibited in the presence of the TβRI kinase inhibitor. Furthermore, immunoblotting with a phosphotyrosine antisem confirmed that PDGFRβ was phosphorylated in response to PDGF-BB stimulation and that phosphorylation was suppressed upon treatment with the PDGFRβ inhibitor imatinib (Fig. 1C).

To investigate whether the complex between PDGFRβ and TβRI could also be demonstrated in untransfected cells, we subjected human dermal primary fibroblasts to immunoprecipitation with antibodies against TβRI, followed by immunoblotting with a PDGFRβ antisem; a band with the expected
PDGFRβ, TβRI, and CD44 Modulate Signaling and Stability

FIGURE 1. PDGFRβ forms a physical complex with TβRI and -II. A and B, Cos1 cells were transiently transfected with PDGFRβ-HA (A and B), TβRI-FLAG (A, left panel), TβRII-FLAG (A, right panel), a truncated PDGFRβ (PDGFRβ-ECTM-HA) expressing only the extracellular and transmembrane parts of the receptor (B), and/or empty vectors. After 48 h, lysates were prepared and subjected to immunoprecipitation (IP) using FLAG or HA antibodies, and proteins were separated by SDS-PAGE. Total cell lysates were run in parallel. Immunoblotting (IB) was performed with FLAG and HA antibodies; β-actin was used as a loading control. C, Cos-1 cells were transiently transfected with PDGFRβ-HA, TβRII-His, and/or empty vectors. After 24 h, cells were starved for another 24 h and then stimulated with combinations of PDGF-BB (7 min, 10 ng/ml), PDGFRβ inhibitor imatinib (1 h, 5 μM), TGFβ (1 h, 1 ng/ml), TβRI inhibitor GW6604 (2 h, 6 μM), DMSO control (2 h), or starvation medium alone. Cells were lysed, and the lystate was subjected to immunoprecipitation with FLAG antibodies, and proteins were separated by SDS-PAGE. Total cell lysates (TCL) were run in parallel. Proteins were detected by immunoblotting with specific antibodies against the HA and FLAG tags, phosphotyrosine, phospho-Smad2, and β-actin. D, human dermal primary fibroblasts were immunoprecipitated using a TβRI antibody or IgG isotype control, followed by immunoblotting with specific PDGFRβ and TβRI antibodies. Representative data from at least three independent experiments are shown.

size of PDGFRβ was observed (Fig. 1D), suggesting that also endogenous TβRI and PDGFRβ form a complex. Taken together, our results show that PDGFRβ and TβRI form a complex, that the interaction is independent on ligand binding and receptor kinase activities, and that the interaction is mediated by the extracellular or transmembrane regions of PDGFRβ.

**PDGFRβ Affects Stability and Downstream Signaling of TβRI**—Following the observation that PDGFRβ and TβRI form a complex, we investigated whether the receptors influence each other’s cell surface residency and signaling. Knockdown of PDGFRβ by siRNA resulted in decreased amounts of TβRI at the cell surface, as shown by labeling cell-surface proteins with biotin and monitoring the amount of biotinylated receptors left on the surface after stimulation with TGFβ (Fig. 2A). Furthermore, the total amount of TβRI in the cell lysate was decreased when PDGFRβ was silenced (Fig. 2A). This effect was not an unspecific off-target effect of the siRNA used, because a second siRNA directed against a single nonoverlapping sequence in PDGFRβ (Ambion) gave the same results (data not shown). In accordance with a role for PDGFRβ in stabilization of TβRI, silencing of PDGFRβ delayed TGFβ-induced phosphorylation of Smad2 (Fig. 2B). Moreover, 1 h of stimulation with PDGF-BB resulted in less TβRI on the cell surface (Fig. 2C).

We then investigated whether TGFβ inversely affects PDGFRβ signaling. There was no effect of TGFβ stimulation on the tyrosine phosphorylation of PDGFRβ when up to 20 ng/ml TGFβ was used for 7 min to 4 h (data not shown). TGFβ treatment did not alter the amount of PDGFRβ on the cell surface (Fig. 2).

**PDGF-BB Induces Phosphorylation of Smad2**—Interestingly, we found that Smad2 was phosphorylated in human dermal fibroblasts in response not only to TGFβ but also to PDGF-BB (Fig. 3). Smad2 phosphorylation was induced about 5-fold more effectively by TGFβ than by PDGF-BB (Fig. 3A), but with similar kinetics by the two ligands, with a peak after about an hour (data not shown). PDGF-BB induced maximal Smad2-phosphorylation already at 2 ng/ml PDGF-BB, when the PDGF-BB-induced phosphorylation of PDGFRβ was only partial (data not shown).

The PDGF-BB-induced Smad2 phosphorylation was attenuated by specific silencing of PDGFRβ with siRNA (Fig. 3B) or by treatment with AG1296, an inhibitor of the kinase activity of PDGFRβ (Fig. 3C), indicating that PDGF-BB binding and activation of its receptor is important for Smad2 activation. Furthermore, the PDGF-BB-induced Smad2 phosphorylation was inhibited by treatment with GW6604, an inhibitor of the kinase activity of TβRI (Fig. 3D), indicating that the kinase activity of TβRI is needed for PDGF-BB-induced phosphorylation of Smad2. Moreover, we observed that antibodies that block the binding of TGFβ to TβRI abrogated PDGF-BB-induced Smad2 phosphorylation (Fig. 3E), indicating that PDGF-BB induces
Smad2 via induction or activation of TGFβ. Because the kinetics of Smad2 phosphorylation was similar after PDGF-BB or TGFβ stimulation, it is likely that PDGF-BB stimulation leads to activation of latent TGFβ produced by the cells or present in the cell culture medium.

Low molecular weight kinase inhibitors were used to investigate the mechanism through which PDGF-BB induces Smad2 phosphorylation. The Src kinase inhibitor SU6656 reduced PDGF-BB-induced phosphorylation of Smad2 (Fig. 3A). The inhibitor was used at a level that inhibited Src, determined as decreased phosphorylation of the downstream substrate STAT3 (45), but not the autophosphorylation of PDGFR as decreased phosphorylation of the downstream substrate inhibitor was used at a level that inhibited Src, determined PDGF-BB-induced phosphorylation of Smad2 (Fig. 3B). The Src kinase inhibitor SU6656 reduced the phosphorylation status of Smad2. The blots were quantified, and phosphorylated Smad2 relative to GAPDH was determined (asterisk indicates $p < 0.05$ with ratio paired $t$ test). As control, nonbiotinylated cells were treated the same way. $B$, cells were lysed and subjected to SDS-PAGE and immunoblotting to determine the phosphorylation status of Smad2. The blots were quantified, and phosphorylated Smad2 relative to GAPDH was determined ($B$, lower panel). Representative experiments of at least three independent experiments are shown. Asterisk indicates $p < 0.05$ using Wilcoxon matched pair signed rank test to compare siRNA control with siRNA against PDGFRβ. TCL, total cell lysates.

PDGF-BB, TβRI, and CD44 Modulate Signaling and Stability

**FIGURE 2. PDGFRβ affects the stability and downstream signaling of TβRI.** $A$ and $B$, human dermal primary fibroblasts were either transfected with siRNA against PDGFRβ or scrambled control ($A$ and $B$) or left untransfected ($C$), then starved, and stimulated ($stim$) for up to $1$ h with TGFβ (1 ng/ml) ($A$–$C$) and PDGF-BB (10 ng/ml) ($C$). $A$ and $C$, cells were placed on ice to stop membrane trafficking; the cell-surface proteins were then labeled using sulfo-NHS-SS-biotin, and biotin that remained unbound was quenched. Cells were lysed, and biotinylated cell-surface proteins were precipitated using streptavidin-coupled magnetic beads. Proteins were separated by SDS-PAGE and immunoblotted for PDGFRβ and TβRI. The amount of PDGFRβ and TβRI left on the cell surface (relative to GAPDH) was quantified ($C$, lower panel indicates fold change of mean values with mean ± S.E. of five experiments; asterisk indicates $p < 0.05$ with ratio paired $t$ test). As control, nonbiotinylated cells were treated the same way. $B$, cells were lysed and subjected to SDS-PAGE and immunoblotting to determine the phosphorylation status of Smad2. The blots were quantified, and phosphorylated Smad2 relative to GAPDH was determined ($B$, lower panel). Representative experiments of at least three independent experiments are shown. Asterisk indicates $p < 0.05$ using Wilcoxon matched pair signed rank test to compare siRNA control with siRNA against PDGFRβ. TCL, total cell lysates.
FIGURE 3. PDGF-BB induces phosphorylation of Smad2 as well as expression of PAI-1, and the PDGF-BB-induced Smad2 phosphorylation is dependent on the kinase activities of PDGFRβ and TβRI, as well as on Src kinase and TGFβ. A, human dermal primary fibroblasts were starved and stimulated (stim) for 1 h with 1 ng/ml TGFβ or 2 ng/ml PDGF-BB. Cells were then lysed and subjected to SDS-PAGE and immunoblotting (IB), with P-Smad2 and Smad2 antisera, and the amount of phosphorylated Smad2 relative to total Smad2 was quantified (A, lower panel indicates fold change compared with TGFβ of mean values, with S.E., of six experiments; asterisk indicates p value < 0.05 with ratio paired t test; three asterisks denote p < 0.01). B, human dermal primary fibroblasts were transfected with either siRNA against PDGFRβ or a scrambled control, starved, and stimulated for 30 min or 1 h with 2 ng/ml PDGF-BB. Cells were then lysed and subjected to SDS-PAGE and immunoblotting, as stated below. C–H, human dermal primary fibroblasts were starved and pretreated for 8 h with 10 μM PDGFRβ kinase inhibitor AG1296 (C), for 2 h with 16 μM TβRI kinase inhibitor GW6604 (D and H), for 1 h with 20 μg/ml TGFβ blocking antibody (E), for 1 h with 1.5 μM Src inhibitor SU6656 (F), or for 2 h with 20 μM cycloheximide (G). Cells were then starved and stimulated for indicated periods with 2 ng/ml PDGF-BB (C–H) and 1 ng/ml TGFβ (E and H), then lysed and subjected to SDS-PAGE and immunoblotting with antibodies against phospho-Smad2, Smad2, phosphotyrosine, PDGFRβ (CTβ), phospho-STAT3, PAI-1, and GAPDH (loading control). Representative experiments from at least three independent experiments are shown. CHX, cycloheximide.
PDGFRβ, TβRI, and CD44 Modulate Signaling and Stability

We have demonstrated in Figs. 1 and 5 and in a previous publication (22) that PDGFRβ, TβRI, and CD44 interact pairwise, we examined the possibility that these three molecules are present in the same complex at the same time. Immunoprecipitations of overexpressed PDGFRβ-HA, TβRI-FLAG, and CD44-6myc in Cos1 cells in different combinations with either anti-Myc, anti-FLAG, or anti-HA antibodies demonstrated that all three receptors could be specifically pulled down with either of the antibodies, confirming that the three receptors interact pairwise in these cells (Fig. 6A). An approach with two sequential immunoprecipitations further suggested that all three receptors can form a ternary complex (data not shown).

To investigate whether the complex between PDGFRβ-HA and TβRI-FLAG is dependent on CD44, we silenced CD44 by siRNA in Cos1 cells overexpressing PDGFRβ-HA and TβRI-FLAG. We then measured the amount of complex between PDGFRβ and TβRI, as seen by PDGFRβ pulled down by FLAG antibody, followed by immunoblotting with HA antibody. The amount of PDGFRβ pulled down was unaffected by the presence or absence of CD44 (Fig. 6B); it thus appears that even though CD44 binds to both PDGFRβ and TβRI, it is not crucial for the interaction between them. To further investigate this interaction, we performed PLA with antibodies against PDGFRβ and TβRI in foreskin fibroblasts with or without silencing of CD44 by siRNA. PLA signals were observed when the specific antibodies were used but not in the controls where one primary antibody was replaced by control IgG or a secondary antibody was omitted. Software quantification of the number of dots revealed no significant differences in the complex between PDGFRβ and TβRI in the presence of absence of CD44 (Fig. 6C). We finally investigated whether formation of the PDGFRβ-TβRI complex was affected by overexpression of CD44; no difference in the amount of complex between PDGFRβ and TβRI was observed upon transfection of Cos1 cells with increasing amounts of CD44 – 6myc-vector (Fig. 6D).

Depletion of CD44 Increases Signaling via PDGFRβ and TβRI by Stabilization of the Proteins—Because CD44 interacted with PDGFRβ and TβRI (Figs. 5 and 6), and has previously been reported to modulate the signaling pathways of both PDGFRβ (22) and TβRI (23, 24), we investigated the role of CD44 during signaling via PDGFRβ and TβRI in fibroblast cultures. Both PDGFRβ-BB-mediated (Fig. 7A) and TGFβ-mediated (Fig. 7B) phosphorylation of Smad2 was enhanced in cells depleted of CD44. There was also a marked increase in total Smad2 protein and ERK1/2 MAPK, as seen upon CD44 knockdown (data not shown), the increase in signaling was likely due to increased stability of TβRI and Smad2. Likewise, enhanced expression of PDGFRβ protein (but not PDGFRβ mRNA; data not shown), as well as enhanced and prolonged PDGFR-BB-induced phosphorylation of PDGFRβ and ERK1/2 MAPK, was observed upon CD44 silencing (Fig. 7C). CD44 thus has a negative regulatory effect on the signaling via both PDGFRβ and TβRI.

DISCUSSION

We demonstrate that the receptors for PDGFRβ and TGFβ interact with each other, as well as with CD44, and that CD44 is not essential for the interaction between PDGFRβ and TβRI. Moreover, we demonstrate that the presence of PDGFRβ correlates to increased levels of TβRI and that PDGFRβ-induced migration depends on TβRI activity.

The expressions of PDGFR receptors and PDGF isoforms are enhanced during TGFβ-induced EMT (32, 34). In colorectal cancer, PDGFRβ expression correlates with poor prognosis and low overall survival, and an inhibitor of TβRI reduced PDGFRβ expression and PDGF-induced tumor cell invasion (33). This is in accordance with our finding that PDGFR-BB-induced migration is inhibited by blocking TβRI kinase activity. The commonly seen induction of PDGFRβ in carcinomas opens up the possibility that the interactions between TβRI, PDGFRβ, and CD44 occur in epithelial cells undergoing EMT. Also in gliomas, TGFβ signaling through Smads activates PDGF-BB expression and secretion, and the effect on proliferation caused...
by TGFβ depends on PDGFRβ signaling (48). The cross-talk between PDGFRβ and TβRII described in this study may thus have widespread implications both in normal and tumor cells and in cancer metastasis.

**PDGF-BB-induced Smad2 Phosphorylation** —Interestingly, we found that PDGF-BB promotes signaling through the TGFβ pathway because it induces Smad2 phosphorylation and expression of the TGFβ-responsive gene PAI-1. The PDGF-BB-induced Smad2 phosphorylation was dependent on active PDGF and TGFβ receptor kinases, Src kinase, and active TGFβ. Thus, although the exact mechanism behind PDGF-BB-induced Smad2 phosphorylation remains to be elucidated, our observations support the notion that PDGF-BB, in an Src-dependent manner, promotes activation of latent TGFβ derived either from the FCS in the culture medium or secreted by the cells.

Because the phosphorylation of Smad2 by PDGF-BB occurred also when protein translation was blocked by cycloheximide, neo-synthesis of TGFβ was not needed for Smad2 activation. The fast kinetics, similar to that of TGFβ itself, also makes neosynthesis of TGFβ unlikely as a mechanism. Activation of TGFβ is, however, a fast event and could be involved in the PDGF-BB-induced phosphorylation of Smad2. TGFβ can be activated from its latent form by several mechanisms, including proteolysis by e.g. matrix metalloproteinase 9, plasmin, or cathepsin (28, 49). Among these proteases, matrix metalloproteinase 9 is an especially interesting candidate for this study, because it can be localized to the plasma membrane by interaction with CD44, thereby promoting tumor invasion of mammary carcinomas (27, 28). However, a panel of general protease inhibitors did not inhibit PDGF-BB-induced Smad2 phosphorylation in our cells (data not shown); thus, it remains to be elucidated whether PDGF-BB promotes a proteolytic activation of TGFβ.

Several α,β-integrins, such as α,β1, α,β3, α,β5, α,β6, and α,β9, have also been implicated in the activation of latent TGFβ (50). Of these integrins, α,β1, is of special interest for this study because there is a tight connection with signaling via PDGF receptors (51–53). PDGFRβ, Src, and TβRII all co-coprecipitate with integrin α,β1 in several cell types, including fibroblasts (51, 53). Furthermore, Src association with α,β1 is augmented by PDGF-BB stimulation, as well as binding to the α,β1 ligand tenascin-C (53, 54). Interestingly, PDGF-BB regulates recycling of α,β1 from early endosomes to the plasma membrane (52). A possible mechanism for the induction of Smad2 phosphorylation in our dermal fibroblasts is thus that PDGF-BB stimulation localizes α,β1 to the plasma membrane, where it activates latent TGFβ. This possibility is currently under investigation.

Another possible explanation for the induction of Smad2 phosphorylation in response to PDGF-BB is that PDGF-BB binds directly to the TGFβ receptors. There is no sequence homology between PDGF and TGFβ, but there is a topological similarity (55). Although this possibility cannot be completely excluded, it is unlikely because PDGFRβ is needed for PDGF-BB-induced Smad2 phosphorylation. Another possible mechanism is that PDGF-BB activates Srp, which has been demonstrated to activate TGFβ signaling by tyrosine phosphorylation of TβRII (56, 57). However, Src-induced phosphorylation of TβRII has only been demonstrated to induce non-Smad signaling through the MAPK pathway (57). Moreover, we found that TGFβ antibodies inhibit PDGF-BB-induced Smad2 phosphorylation; thus, it is unlikely that direct tyrosine phosphorylation of TβRII by Src contributes to the PDGF-BB-induced Smad2 phosphorylation in our cells.

Finally, PDGF-BB-induced phosphorylation of Smad2 could be due to inhibition of phosphatases or deubiquitinases that normally would shut off the activation of Smad2, e.g. induced by autocrine TGFβ. It is also possible that PDGFRβ, directly or indirectly, sequesters Smad2 in an unfavorable location. However, these possibilities are unlikely because the Smad2 phosphorylation was blocked by TGFβ antibodies and because we
FIGURE 6. PDGFRβ, TβRI, and CD44 all bind each other, but the complex between PDGFRβ and TβRI is not dependent on CD44. A, Cos1 cells were transiently transfected with PDGFRβ-HA, TβRI-FLAG, and CD44–6myc or correspondingly tagged empty vectors. After 48 h, cell lysates were immunoprecipitated (IP) using FLAG, HA, or Myc antibodies. Proteins were released from beads by boiling in reducing sample buffer and subjected to SDS-PAGE and immunoblotting (IB) with antibodies against CD44, HA, and FLAG or GAPDH as loading control. Total cell lysates (TCL) were analyzed in parallel. B, Cos1 cells were transiently transfected with CD44 siRNA for 24 h and then with TβRI-FLAG and PDGFRβ-HA vectors for another 48 h. Cells were lysed and immunoprecipitated with FLAG antibodies, separated by SDS-PAGE, and detected by immunoblotting for CD44 and the HA and FLAG tags. C, BJ-hTERT foreskin fibroblasts were grown in 8-well chambers and transiently transfected with siRNA against CD44 or a scrambled control. Following starvation, cells were stimulated for 7 min with PDGF-BB (20 ng/ml), 2 h with hyaluronan (200 μg/ml), 1 h with TGFβ (1 ng/ml), or 1 h with 10% FBS. Cells were fixed and PLA was performed with mouse anti-PDGFRβ and rabbit anti-TβRI antibodies, followed by anti-mouse and anti-rabbit PLA probes conjugated with priming and nonpriming oligonucleotides. F-actin was stained with FITC-conjugated phalloidin. Single protein-protein interactions were visualized by fluorescence microscope as red dots. PLA signals per cell were quantified with Duolink Image Tool according to the manufacturer’s instructions. Average is indicated in the graph by horizontal lines. D, Cos1 cells were transfected with PDGFRβ-HA and TβRI-FLAG, in combination with varying amounts of CD44-myc (0.1, 0.5, or 2 μg/sample) or empty vector. Cells were lysed, and immunoprecipitated with FLAG antibody and subjected to SDS-PAGE. The samples were then immunoblotted with specific antibodies against the FLAG and HA tags and CD44. Total cell lysates were run in parallel. Representative experiments out of three independent experiments are shown.

FIGURE 7. Knockdown of CD44 stabilizes the levels of PDGFRβ and Smad2. Human dermal primary fibroblasts were transfected with siRNA against CD44 or a scrambled control, starved, and stimulated for indicated time periods with either 2 ng/ml PDGF-BB (A), 1 ng/ml TGFβ (B), or 10 ng/ml PDGF-BB (C). Lysates were subjected to SDS-PAGE and immunoblotting with antibodies against phospho-Smad2, Smad2, CD44, phospho-ERK1/2, ERK1/2, and GAPDH (loading control). Representative experiments of three independent experiments are shown.
did not observe any co-immunoprecipitation of PDGFβR and Smad2 (data not shown).

**CD44 Exerts a Negative Modulatory Effect on PDGF-BB and TGFβ Signaling**—We have previously reported that hyaluronan-activated CD44 mediates recruitment of a tyrosine phosphatase to PDGFβR in foreskin fibroblasts and thus negatively regulates PDGF-BB signaling (22). Also in dermal fibroblasts, CD44 had a negative effect on signaling through PDGFβR. In accordance with the high concentration of hyaluronan in skin, our dermal fibroblasts produced high amounts of hyaluronan even during unstimulated and starved conditions. It is thus possible that the lack of hyaluronan binding to CD44, with a concomitant loss of dephosphorylation of PDGFβR, contributes to the increased PDGF-BB response observed upon knockdown of CD44. However, although such a dephosphorylation mechanism could contribute to the suppressive effect of CD44 on PDGFβR and TβRI signaling, most of the suppressive effect seems to be due to destabilization of the receptors. We thus confirm the negative modulatory role of CD44 in human dermal fibroblasts and report a novel mechanism of CD44-dependent modulation of growth factor signaling.

In intestinal epithelial cells, the binding of CD44 to hyaluronan has a positive effect on the phosphorylation of PDGFβR (58). Because this was demonstrated in epithelial cells, although this study and our previous work have used dermal fibroblasts, it is possible that the differences are cell type-dependent. In proximal renal tubular cells, hyaluronan binding to CD44 redistributes TβRI to lipid rafts, thus negatively affecting the signaling of TβRI (36). This effect is blocked by MEK inhibitors, indicating the importance of ERK MAPK signaling. Because this is in accordance with our results that PDGF-BB stimulation removes TβRI from the plasma membrane, it is possible that PDGFβR and CD44 together regulate the localization and signaling of TβRI.

In summary, we have demonstrated cross-talk between the receptors for TGFβ and PDGF-BB and the adhesion receptor CD44. Such cross-talk could have important functions for several pathologies with dysfunctional regulation of PDGF-BB and TGFβ, such as inflammation and cancer.

**Acknowledgment**—We thank Aino Ruusala for technical assistance.

**REFERENCES**

1. Heldin, C. H., and Westermark, B. (1999) Mechanism of action and in vivo role of platelet-derived growth factor. *Physiol. Rev.* 79, 1283–1316
2. Andrae, J., Gallini, R., and Betsholtz, C. (2008) Role of platelet-derived growth factors in physiology and medicine. *Genes Dev.* 22, 1276–1312
3. Hellberg, C., Schmees, C., Karlsson, S., Ahgren, A., and Heldin, C. H. (2009) Activation of protein kinase Cα is necessary for sorting the PDGFβ-receptor to Rab4a-dependent recycling. *Mol. Biol. Cell.* 20, 2856–2863
4. Shi, Y., and Massagué, J. (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. *Cell* 113, 685–700
5. Zhang, Y. E. (2009) Non-Smad pathways in TGF-β signaling. *Cell Res.* 19, 128–139
6. Shibanaka, Y., Hayashi, H., Umemura, I., Fujisawa, Y., Okamoto, M., Takai, M., and Fujita, N. (1994) Ecolision hormone-mediated signal transduction in the silkworm abdominal ganglia: Involvement of a cascade from inositol(1,4,5)triphosphate to cyclic GMP. *Biochem. Biophys. Res. Commun.* 198, 613–618
7. Chen, Y. G. (2009) Endocytic regulation of TGF-β signaling. *Cell Res.* 19, 58–70
8. Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L., and Wrana, J. L. (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor. *Cell* 95, 779–791
9. Di Guglielmo, G. M., Le Roy, C., Goodfellow, A. F., and Wrana, J. L. (2003) Distinct endocytic pathways regulate TGF-β receptor signalling and turn-over. *Nat. Cell Biol.* 5, 410–421
10. Feng, X. H., and Derynck, R. (2005) Specificity and versatility of tgf-β signaling through Smads. *Annu. Rev. Cell Dev. Biol.* 21, 659–693
11. Heldin, C. H., Vanlandewijck, M., and Moustakas, A. (2012) Regulation of EMT by TGFβ in cancer. *FEBS Lett.* 586, 1599–1970
12. Moustakas, A., and Heldin, P. (2014) TGFβ and matrix-regulated epithelial to mesenchymal transition. *Biochim. Biophys. Acta* 10.1016/j. bbagen.2014.02.004
13. Riklin, D. B. (2005) Latent transforming growth factor-β (TGF-β) binding proteins: orchestrators of TGF-β availability. *J. Biol. Chem.* 280, 7479–7412
14. Ponta, H., Sherman, L., and Herrlich, P. A. (2003) CD44: from adhesion molecules to signalling regulators. *Nat. Rev. Mol. Cell Biol.* 4, 33–45
15. Toole, B. P. (2009) Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. *Clin. Cancer Res.* 15, 7462–7468
16. Bourguignon, L. Y. (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytokinosis function promotes tumor progression. *Semin. Cancer Biol.* 18, 251–259
17. Skandalis, S. S., Koizumi, I., Enström, U., Hellman, U., and Heldin, P. (2010) Proteomic identification of CD44 interacting proteins. *ILIIBM Life Sci.* 62, 833–840
18. Morrison, H., Sherman, L. S., Legg, J., Bani, F., Isacke, C., Haïpek, C. A., Gutmann, D. H., Ponta, H., and Herrlich, P. (2001) The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. *Genes Dev.* 15, 968–980
19. Lee, J. L., Wang, M. J., and Chen, J. Y. (2009) Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. *J. Biol. Chem.* 185, 949–957
20. Ghatak, S., Misra, S., and Toole, B. P. (2005) Hyaluronan constitutively phosphorylates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. *J. Biol. Chem.* 280, 8875–8883
21. Kim, Y., Lee, Y. S., Choe, J., Lee, H., Kim, Y. M., and Jeoung, D. (2008) CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. *J. Biol. Chem.* 283, 22513–22528
22. Li, L., Heldin, C. H., and Heldin, P. (2006) Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44. *J. Biol. Chem.* 281, 26512–26519
23. Bourguignon, L. Y., Singleton, P. A., Zhu, H., and Zhou, B. (2002) Hyaluronan promotes signal interaction between CD44 and the transforming growth factor β receptor I in metastatic breast tumor cells. *J. Biol. Chem.* 277, 39703–39712
24. Ito, T., Williams, J. D., Fraser, D., and Phillips, A. O. (2004) Hyaluronan attenuates transforming growth factor-BI-mediated signaling in renal proximal tubular epithelial cells. *Ann. J. Pathol.* 164, 1979–1988
25. Oriian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P., and Ponta, H. (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. *Genes Dev.* 16, 3074–3086
26. Wakahara, K., Kobayashi, H., Yagyu, T., Matsuzaki, H., Kondo, T., Kurita, N., Sekino, H., Inagaki, K., Suzuki, M., Kanayama, N., and Terao, T. (2005) Bikunin down-regulates heterodimerization between CD44 and growth factor receptors and subsequently suppresses agonist-mediated signaling. *J. Cell. Biochem.* 94, 995–1009
27. Yu, Q., and Stamenkovic, I. (1999) Localization of matrix metalloprotease-9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. *Genes Dev.* 13, 35–48
28. Yu, Q., and Stamenkovic, I. (2000) Cell surface-localized matrix metalloprotease-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. *Genes Dev.* 14, 163–176
29. Yu, Q., and Stamenkovic, I. (2004) Transforming growth factor-β facili-
tates breast carcinoma metastasis by promoting tumor cell survival. Clin. Exp. Metastasis 21, 235–242.

30. Battegay, E. J., Seifert, R. A., Bowen-Pope, D. F., and Ross, R. (1990) TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63, 515–524.

31. Seymour, L., Dajee, D., and Bezwoda, W. R. (1993) Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res. Treat. 26, 247–252.

32. Jechlinger, M., Grunert, S., Tamir, I. H., Janda, E., Lüdemann, S., Waerner, T., Seither, P., Weith, A., Beug, H., and Kraut, N. (2003) Expression profiling of epithelial plasticity in tumor progression. Oncogene 22, 7155–7169.

33. Steller, E. J., Raats, D. A., Koster, J., Rutten, B., Govaert, K. M., Emmink, B. L., Snoeren, N., van Hooff, S. R., Hoelstege, F. C., Maas, C., Borel Rinkes, I. H., and Kränenburg, O. (2013) PDGFRβ promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia 15, 204–217.

34. Jechlinger, M., Sommer, A., Moriggl, R., Seither, P., Kraut, N., Capodieci, P., Donovan, M., Cordon-Cardo, C., Beug, H., and Grünert, S. (2006) Autocrine PDGF signaling promotes mammary cancer metastasis. J. Clin. Invest. 116, 1561–1570.

35. Gottzmann, J., Fischer, A. N., Zojev, M., Mikula, M., Proell, V., Huber, H., Jechlinger, M., Waerner, T., Weith, A., Beug, H., and Mikulits, W. (2006) A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes. Oncogene 25, 3170–3185.

36. Ito, T., Williams, J. D., Fraser, D. J., and Phillips, A. O. (2004) Hyaluronan regulates transforming growth factor-β1 receptor compartmentalization. J. Biol. Chem. 279, 25326–25332.

37. Kovalenko, M., Denner, K., Strömström, J., Persson, C., Gross, S., Jandt, E., Vilella, R., Böhmer, F., and Ostman, A. (2000) Site-selective dephosphorylation of the platelet-derived growth factor β-receptor by the receptor-like protein-tyrosine phosphatase DEP-1. J. Biol. Chem. 275, 16219–16226.

38. Lammich, S., Okochi, M., Takeda, M., Kaether, C., Capell, A., Zimmer, A. K., Edbauer, D., Walter, J., Steiner, H., and Haass, C. (2002) Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an APP-like peptide. J. Biol. Chem. 277, 44754–44759.

39. Yao, D., Ehrlich, M., Henis, Y. I., and Leof, E. B. (2002) Transforming growth factor-β receptors interact with AP2 by direct binding to β2 subunit. Mol. Biol. Cell 13, 4001–4012.

40. Franzén, P., ten Dijke, P., Ichijo, H., Yamashita, H., Schulz, P., Heldin, C. H., and Miyazono, K. (1993) Cloning of a TGF β type I receptor that forms a heteromeric complex with the TGF β type II receptor. Cell 75, 681–692.

41. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and Weinberg, R. A. (1999) Creation of human tumour cells with defined genetic elements. Nature 400, 464–468.

42. Jalkanen, S., Bargatzke, R. F., de los Tojos, J., and Butcher, E. C. (1987) Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85–95 kDa glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J. Cell Biol. 105, 983–990.

43. Karlsson, S., Kowanetz, K., Sandin, A., Persson, C., Ostman, A., Heldin, C. H., and Hellberg, C. (2006) Loss of T-cell protein tyrosine phosphatase induces recycling of the platelet-derived growth factor (PDGF) β-receptor but not the PDGFRα-receptor. Mol. Biol. Cell 17, 4846–4855.

44. Piek, E., Moustakas, A., Kurisaki, A., Heldin, C. H., and ten Dijke, P. (1999) TGF-β type I receptor/ALK-5 and Smad proteins mediate epithelial mesenchymal differentiation in NMuMG breast epithelial cells. J. Cell Sci. 112, 4557–4568.

45. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Grooth, R. P., and Jove, R. (1998) Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18, 2545–2552.

46. Jarvis, M., Paulson, J., Weibrich, I., Leuchowius, K. J., Andersson, A.-C., Wählby, C. and Takeda, M., Botling, J., Smarkova, T., Markova, B., Ostman, A., Landegren, U., and Söderberg, O. (2007) In situ detection of phosphorylated PDGFR β using a generalized proximity ligation method. Mol. Cell Proteomics 6, 1500–1509.

47. Söderberg, O., Gullberg, M., Jarvis, M., Ridderstråle, K., Leuchowius, K. J., Jarvis, J., Wester, K., Hybring, P., Larsson, L. G., and Landegren, U. (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3, 995–1000.

48. Bruna, A., Darken, R. S., Rojo, F., Cao, A., Peñuelas, A., Arias, A., Paris, R., Tortosa, A., Mora, J., Baselga, J., and Seoane, J. (2007) High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11, 147–160.

49. Lyons, R. M., Keski-Oja, J., and Moses, H. L. (1988) Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J. Biol. Chem. 106, 1659–1665.

50. Ludbrook, S. B., Barry, S. T., Delves, C. J., and Horgan, C. M. (2003) The integrin αvβ3 is a receptor for the latency-associated peptides of transforming growth factors β1 and β3. Biochem. J. 369, 311–318.

51. Woodard, A. S., García-Cardefga, G., Leong, M., Madri, J. A., Sessa, W. C., and Languino, L. R. (1998) The synergistic activity of αvβ3 integrin and PDGF receptor increases cell migration. J. Cell Sci. 111, 469–478.

52. Roberts, M., Barry, S., Woods, A., van der Sluijs, P., and Norman, J. (2001) PDGF-regulated rbα4-dependent recycling of αvβ3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr. Biol. 11, 1392–1402.

53. Ishigaki, T., Inamaka-Yoshida, K., Shimojo, N., Matsushima, S., Taki, W., and Yoshida, T. (2011) Tenascin-C enhances cross-talk signaling of integrin αvβ3/PDGFR-β complex by SRC recruitment promoting PDGF-induced proliferation and migration in smooth muscle cells. J. Cell Physiol. 226, 2617–2624.

54. Ding, Q., Stewart, J., Jr., Olman, M. A., Klose, M. R., and Gladson, C. L. (2003) The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J. Biol. Chem. 278, 39882–39891.

55. Murray-Rust, J., McDonald, N. Q., Blundell, T. L., Hosang, M., Oefner, C., Winkler, F., and Bradshaw, R. A. (1993) Topological similarities in TGF-β2, PDGF-BB, and NGF define a superfamily of polypeptide growth factors. Structure 1, 153–159.

56. Galliher, A. J., and Schiemann, W. P. (2007) Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 67, 3752–3758.

57. Galliher, A. J., and Schiemann, W. P. (2006) β3 integrin and Src facilitate transforming growth factor-β-mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 8, R42.

58. Misra, S., Toole, B. P., and Ghatak, S. (2006) Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J. Biol. Chem. 281, 34936–34941.